Characterizing Pharmacokinetic–Pharmacodynamic Relationships and Efficacy of PI3Kδ Inhibitors in Respiratory Models of TH2 and TH1 Inflammation-Reference-Cited by-同舟云学术

Characterizing Pharmacokinetic–Pharmacodynamic Relationships and Efficacy of PI3Kδ Inhibitors in Respiratory Models of TH2 and TH1 Inflammation

Published:2019-02-25 Issue:2 Volume:369 Page:223-233
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

McLeod Robbie L.,Gil Malgorzata A.,Chen Dapeng,Cabal Antonio,Katz Jason,Methot Joey,Woodhouse Janice D.,Dorosh Lauren,Geda Prasanthi,Mehta Khamir,Cicmil Milenko,Baltus Gretchen A.,Bass Alan,Houshyar Hani,Caniga Michael,Yu Hongshi,Gervais Francois,Alves Stephen,Shah Sanjiv

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference52 articles.

1. New anti-inflammatory targets for chronic obstructive pulmonary disease

2. Therapeutic approaches to asthma–chronic obstructive pulmonary disease overlap syndromes

3. Lung tissue neutrophil content as a determinant of ozone-induced injury;Bassett;J Toxicol Environ Health A,2000

4. Effect of an NK1/NK2Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma

5. Calzetta L Cazzola M Matera MG Rogliani P (2019) Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple combination therapy in COPD. Chest DOI: 10.1016/j.chest.2018.12.016 [published ahead of print].

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model;Clinical Cancer Research;2023-04-18

2. Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators;Journal of Medicinal Chemistry;2021-04-02

3. Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review;Journal of Clinical Medicine;2020-09-11

4. PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19;Frontiers in Immunology;2020-08-21